emerging trends in non-alcoholic fatty liver disease

186 Pages·2017·14.28 MB·English

Emerging Trends Conference:
EMERGING TRENDS IN
NON-ALCOHOLIC FATTY
LIVER DISEASE
2017
March 18–19
Hyatt Regency on Capitol Hill, Washington, DC
Program Chairs
Zobair M. Younossi, MD, MPH, FAASLD
Keith D. Lindor, MD, FAASLD
Schedule-at-a-Glance and Meeting Locations

Friday, March 17

5:00pm – 7:00pm Registration Regency Foyer

Saturday, March 18

6:30am – 5:00pm Registration Regency Foyer

7:00am – 8:00am Breakfast Regency Foyer

8:00am – 4:40pm General Session Regency Ballroom

10:45am – 10:55am Break Regency Foyer

12:45pm – 1:30pm Lunch Regency Foyer

3:00pm – 3:10pm Break Regency Foyer

4:40pm – 5:30 pm Poster Reception Columbia ABC

Sunday, March 19

6:30am – 10:00am Registration Regency Foyer

7:00am – 8:00am Breakfast Regency Foyer

8:00am – Noon General Session Regency Ballroom

9:50am – 10:00 am Break Regency Foyer

– Notice –

Information may not be recorded, photographed, copied, photocopied, transferred to
electronic format, and reproduced or distributed without the written permission of the
presenter and AASLD.

XXXX
Table of Contents

Continuing Education Information…………………………………………………..1
Disclosures……………………………………………………………………………....2
Course Schedule ……………………………………………………………………….9
Speaker Summaries...........................................................................................14

Saturday, March 18
Clinical, Epidemiologic, Patient-Reported and Economic Burden of NAFLD
Zobair M. Younossi, MD, MPH, FAASLD………………………………………….....15

Long Term Outcomes: Mortality and Causes of Death in NAFLD
Mary E. Rinella, MD, FAASLD ………………………………………………………...20

Will The Epidemic of NAFLD Be Responsible for the Future Burden of HCC?
Elisabetta Bugianesi, MD, PhD.............................................................................22

Is MS the Consequence or Precursor of NASH?
Giulio Marchesini, MD.......................................................................................... 24

Insulin Resistance in NAFLD
Brent A. Neuschwander-Tetri, MD, FAASLD........................................................26

Lipid Abnormalities in NAFLD
Lawrence Serfaty, MD......................................................................................... 29

Cardiovascular Diseases and NAFLD
Francesco Negro, MD..........................................................................................31

Mitochondria and Endoplasmic Reticulum in the Pathogenesis of NASH
Stephen H. Caldwell, MD, FAASLD......................................................................33

The Role White Adipose Tissue in NASH
Vlad Ratziu, MD....................................................................................................37

Gut Microbiome and NAFLD
Kathleen E. Corey, MD, MPH................................................................................40

Fibrogenesis of NASH: What Is Different About It?
Scott L. Friedman, MD, FAASLD...........................................................................42

Experimental Models of NAFLD: Do They Represent the Human Disease?
Anna Mae Diehl, MD, FAASLD..............................................................................44

Regional and Ethnic Differences in NASH
Arun J. Sanyal, MD, FAASLD................................................................................47
NASH in Children
Joel E. Lavine, MD, PhD, FAASLD.........................................................................49

NASH and Bariatric Surgery
Philippe Mathurin, MD, PhD....................................................................................51

NASH and Liver Transplantation
Michael R. Charlton, MD.........................................................................................53

Sunday, March 19
Role of Histopathology in the Clinical Research and Clinical Management of Patients
with NAFLD
Zachary D. Goodman, MD, PhD, FAASLD..............................................................55

The Role Radiologic Modalities for Diagnosing, Staging and Monitoring NASH
Rohit Loomba, MD, MHSc.......................................................................................57

Noninvasive Biomarkers in NASH
Naga P. Chalasani, MD, FAASLD............................................................................59

Serum Fibrosis Markers in NASH
Quentin M. Anstee, MBBS, PhD...............................................................................61

What Are the Best Endpoints for the Clinical Trials of NASH: Investigator and
Regulatory Perspective
Kris V. Kowdley, MD, FAASLD.................................................................................65

Weight Loss and Exercise in NAFLD
Jacob George, PhD, FAASLD..................................................................................67

The Current Medical Treatment for Patients with NASH
Manal F. Abdelmalek, MD, MPH, FAASLD..............................................................69

Emerging Therapy for NASH: Non-antifibrotics
Stephen A. Harrison, MD, FAASLD..........................................................................73

Emerging Therapy for NASH: Antifibrotics
Scott L. Friedman, MD, FAASLD..............................................................................75

Summary of the Meeting: What to Do Next?
Keith D. Lindor, MD, FAASLD................................................................................TBD

Oral Abstract Presentations..................................................................................77
Poster Abstract Summaries...................................................................................93
Hyatt Hotel Map....................................................................................................164
2017 AASLD Emerging Trends Conference:
Emerging Trends in Non-alcoholic Fatty Liver Disease

March 18 – 19, 2017
Hyatt Regency on Capitol Hill
Washington, DC

Program Chairs: Zobair M. Younossi, MD, MPH, FAASLD and Keith D. Lindor, MD, FAASLD

Continuing Education Information
Upon completion of this activity, participants will be able to:
 Recognize the global epidemiology of NAFLD.
 Evaluate the strength/limitation of different diagnostic and prognostic modalities
of NAFLD.
 Review the current and future treatment of NAFLD.

This activity was planned in the context of the following ACGME/IOM/Interprofessional
Education Collaborative competencies: Patient-Centered Care, Evidence-Based
Practice and Medical Knowledge.

Accreditation Statement
The American Association for the Study of Liver Diseases (AASLD) is accredited by the
Accreditation Council for Continuing Medical Education (ACCME) to provide continuing
medical education for physicians.

Continuing Medical Education (CME) Credit Designation
AASLD designates this live activity for a maximum of 11.50 AMA PRA Category 1
Credits™. Physicians should claim only the credit commensurate with the extent of their
participation in the activity.

American Board of Internal Medicine Maintenance of Certification (MOC) Designation
Successful completion of this CME activity, which includes participation in the
evaluation component, enables the participant to earn up to 11.50 MOC points in the
American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC)
program. Participants will earn MOC points equivalent to the amount of CME credits
claimed for the activity. It is the CME activity provider’s responsibility to submit
participant completion information to ACCME for the purpose of granting ABIM MOC
credit.

American Board of Pediatrics Maintenance of Certification
Successful completion of this CME activity, which includes participation in the activity,
with individual assessments of the participant and feedback to the participant, enables
the participant to earn 11.00 MOC points in the American Board of Pediatrics’ (ABP)
Maintenance of Certification (MOC) program. It is the CME activity provider’s
responsibility to submit participant completion information to ACCME for the purpose of
granting ABP MOC credit.
Continuing Medical Education (CME) Evaluation*
Attendees may obtain CME credit and a certificate by completing the electronic meeting
evaluation. A link to the evaluation will be sent to all attendees electronically at the
conclusion of the conference. Once you have completed the evaluation, a certificate will
be emailed to you within three weeks. The CME evaluation deadline is Wednesday,
April 19, 2017.

NOTE: CME credits/MOC points are not available for the following presentations during
the conference:

Session V: Oral Presentations
 VLX103, a New Hepatoselective Investigational Drug Targeting the LPS-TLR4
Pathway in Non-Alcoholic Liver Disease
Patrick Colin, BPharm, PhD
 The Comparative Effect of Liraglutide, Elafibranor and Obeticholic Acid on
NAFLD Activity Score and Fibrosis Stage in a Diet-Induced Obese Mouse Model
of Biopsy-Confirmed Non-Alcoholic Steatohepatitis
Michael Feigh, MD
 Poster Reception and Viewing

Disclosures
This live educational activity has been planned in accordance with AASLD policy and
ACCME Standards of Commercial Support by conference faculty members and the
following AASLD planning committees: Clinical Research Committee and the Governing
Board.

As an accredited provider, AASLD requires individuals involved in the planning of CME
and MOC activities to disclose all financial relationships, including those of their spouse
or partner, with a commercial interest within the past 12 months. A commercial interest
is defined as any entity producing, marketing, re-selling, or distributing health care
goods or services consumed by, or used on, patients. All conflicts of interest are
resolved prior to participation.

Statement on Off-Label and Investigational Use: Speakers are advised to make a
reasonable effort to identify any discussion of off-label or investigative use or application
of a product or device during their presentation.

Financial disclosures will appear at the beginning of each session.

2
Faculty Disclosures

Manal F. Abdelmalek, MD, MPH, FAASLD
Grant/Research Support: Allergan, Gilead Sciences, Genfit Pharmaceuticals, TaiwanJ
Pharma, Intercept, BMS Pharma, NIH/NIDDK, Immuron, Galmed, NGM
Pharmaceuticals, Intercept, Galactin, Madrigal, Conatus, Galactin, Excelanz Consulting:
TaiwanJ Pharma, NGM Pharmaceuticals, BMS Pharma
Speakers' Bureau: Alexion

Reham Abdou, MD
Nothing to disclose, no conflict of interest

Quentin M. Anstee, MBBS, PhD
Grant/Research Support: Abbvie
Advisory Board/Consulting: Intercept Pharmaceuticals, Pfizer, Eli Lilly, Raptor
Pharmaceuticals, Genfit, Abbott Laboratories, Acuitas Medical, Inventiva, Tobira,
Gilead, Janssen

Elisabetta Bugianesi, MD, PhD
Advisory Committees and/or Review Panels: IBSA, Boehringer

Stephen H. Caldwell, MD, FAASLD
Advisory Committees and/or Review Panels: Vital Therapy
Grant/Research Support: Genfit, TaiwanJ, Immuron, Gilead Sciences, Immuron, NGM

Naga P. Chalasani, MD, FAASLD
Consulting: Abbvie, Lilly, DS Biopharma, Tobira, NuSirt, Madrigal, Cempra, Shire,
Allergan
Grant/Research Support: Intercept, Gilead, Galectin

Michael R. Charlton, MD
Grant/Research Support: Intercept, GIlead Sciences, Merck, Janssen, AbbVie, Novartis
Consulting: Gilead Sciences

Patrick Colin, BPharm, PhD
Employee: Verlyx Pharmaceuticals

Kathleen E. Corey, MD, MPH
Advisory Committees and/or Review Panels: Gilead
Speaking and Teaching: Synageva

Michael Feigh, MD
Employee: Gubra

Scott L. Friedman, MD, FAASLD
3
Stock Options: Intercept, Blade Therapeutics, Conatus, DeuteRx, Exalenz, Galectin,
Galmed, Genfit, Glympse, Kinemed, Nimbus, Northern Biologics, Tobira
Therapeutics,BirdRock Bio, Akrana Therapeutics, Scholar Rock
Consulting: Abbvie, Angion, Blade Therapeutics, Blueprint Medicines, Boehringer
Ingelheim, Bristol Myers Squibb, Chemocentryx, Conatus Pharm, Debio
Pharmaceuticals, Deerfield Consulting, DeuteRx, DS Biosciences, Eli Lilly
PHarmaceuticals, Enanta Pharmaceuticals, Exalenz Biosciences, Fibrogen, Fractyl
Bioscience, Galectin Therapeutics, Galmed, Genfit, Genkyotex, Glycotest, GNI Group,
Immune Therapeutics, Intercept, Ironwood Pharmaceuticals, Isis Pharmaceuticals,
Kinemed, Madrigal Pharmaceuticals, Metagenix, Merck Pharmaceuticals, Nimbus
Therapeutics, Nitto Corp., Northern Biologics, Novartis, Ocera Therapeutics, Pfizer Inc,
Raptor Pharmaceuticals, Roche/Genentech Pharmaceuticals, RuiYi, Sandhill Medical
Devices, Scholar Rock, Shire Pharmaceuticals, Synageva BioPHarma, Takeda
Pharmaceuticals, Teva Pharmaceuticals, Tobira Therapeutics, Viking Therapeutics,
Zafgen
Grant/Research Support: Bristol-Myers Squibb, Abbvie, Enanta, Zafgen

Jacob George, PhD, FAASLD
Grant/Research Support: MSD, Abbvie, Gilead, BMS, MSD

Zachary D. Goodman, MD, PhD, FAASLD
Grant/Research Support: Gilead Sciences, Alexion, Conatus, Cempra, Tobira, Exalenz,
Galectin Therapeutics, Intercept

Stephen A. Harrison, MD, FAASLD
Advisory Committees or Review Panels: Merck, Intercept, CLDF, Zafgen, Nimbus
Discovery, Fibrogen, Pfizer, Gilead
Speaking and Teaching: Gilead, CLDF, Abbvie, Merck, Alexion
Consulting: Medivation, NGM Biopharmaceuticals, Alexion
Grant/Research Support: Genfit

Monica A. Konerman, MD
Nothing to disclose, no conflict of interest

Kris V. Kowdley, MD, FAASLD
Speakers' Bureau: Intercept
Grant/Research Support: Abbvie, Evidera, Galectin, Gilead, Immuron, Intercept, Merck,
NGM Biopharma, Novartis,Tobira, Trio Health
Royalties: Up-To-Date
Consulting: Enanta, Gilead, Intercept, NGM Bio

Joel E. Lavine, MD, PhD, FAASLD
Advisory Committees or Review Panels: Janssen
Consulting: Merck, Pfizer, Prestige Brands

Keith D. Lindor, MD, FAASLD
Advisory Committees or Review Panels: Intercept, Shire
4
Rohit Loomba, MD, MHSc
Advisory Committees or Review Panels: Galmed Inc., Arrowhead Research Inc., Tobira
Inc.
Consulting: Gilead Inc., Janssen and Janssen Inc., Zafgen Inc., Alnylam Inc., Corgenix
Inc., Celgene Inc., Inanta Inc., Deutrx Inc.
Grant/Research Support: Daiichi Sankyo Inc., Merck Inc., Immuron Inc., Adheron Inc.,
AGA, Promedior Inc., Kinemed Inc.

Giulio Marchesini, MD
Advisory Committees or Review Panels: Eli Lilly
Grant/Research Support: Merck Sharp & Dome
Speaking and Teaching: Merck Sharp & Dome, Eli Lilly, Astra-Zeneca, Novo Nordisk,
Boerhinger Ingelheim, Janssen, Novartis
Board Membership: Genfit, Novartis, Gilead, Glaxo

Brent A. Neuschwander-Tetri, MD, FAASLD
Advisory Committees or Review Panels: Nimbus Therapeutics, Bristol Myers Squibb,
Boehringer-Ingelheim, Janssen, Conatus, Enanta, Novartis, Galmed, Zafgen, Receptos,
Pfizer, Allergan, MedImmune/AstraZeneca, CoSynance, Tobira

Philippe Mathurin, MD, PhD
Board Membership: MSD, Janssen-Cilag, BMS, Gilead, Abvie, VerlyX, Intercept
Consulting: MSD, Janssen-Cilag, BMS, Gilead, Abvie, Verlyx, Interceptche, Bayer
Francesco Negro, MD
Advisory Committees and/or Review Panels: Gilead, Abbvie, MSD
Grant/Research Support: Gilead, AbbVie

Vlad Ratziu, MD
Advisory Committees and/or Review Panels: GalMed, Abbott, Genfit, Enterome, Gilead
Consulting: Tobira, Intercept, Exalenz, Boehringer-Ingelheim

Mary E. Rinella, MD, FAASLD
Advisory Committees and/or Review Panels: Abbvie, Intercept
Consulting: NGM, Shire, Fibrogen

Arun J. Sanyal, MD, FAASLD
Advisory Committees or Review Panels: Abbott, Bristol Myers, Exhalenz, Genfit, Gilead,
Ikaria, Novartis, Pfizer, Tiziana, Conatus, OWL, Echosens, Immuron
Consulting: Echosens, Enanta, Exhalenz, Genentech, Hemoshear, Immuron, Islet
Sciences, JD Pharma, Merck, Nimbus, Salix, Takeda, Zafgen, Amarin, Vivelyx,
Malinckrodt, Ardelyx, Indalo, Zydus

Lawrence Serfaty, MD
Speaking and Teaching: Janssen, BMS, Gilead, Merck, Abbvie
Consulting: Merck, Gilead, Abbvie, BMS, Janssen, Intercept

5
Maria Stepanova, PhD
Nothing to disclose, no conflict of interest

Zobair M. Younossi, MD, MPH, FAASLD
Advisory Committees and/or Review Panels: Gilead, BMS, Intercept, Abbvie and GSK
Consulting: Gilead, Intercept

Planner Disclosures

Manal Abdelmalek, MD, MPH, FAASLD (Clinical Research Committee)
Consulting: BHV Pharma, TaiwanJ Pharma
Grant/Research Support: Arisaph, Bristol Myers Squibb Pharma, Galmed, Genfit
Pharmaceuticals, Gilead Sciences, Immuron, Intercept, NGM Pharmaceuticals,
NIH/NIDDK, TaiwanJ Pharma, Tobira
Speaking and Teaching: Alexion

Jorge A. Bezerra, MD, FAASLD (Governing Board)
Grant/Research Support: Gilead, Molecular Genetics Laboratory of Cincinnati Children's
Hospital Medical Center, Shyer

Kimberly Ann Brown, MD, FAASLD (Governing Board)
Board Membership: ABIM SEP, AST Finance Committee, CLD Journal, CLDF
Advisory Committee or Review Panel: AbbVie, Bristol-Myers Squibb, Gilead, Merck
Grant/Research Support: AbbVie, Gilead, Hyperion, Janssen, Simply Speaking CME
Other: Medscape – CME content development for HCV

Kenneth D. Chavin, MD, PhD (Clinical Research Committee)
Grant/Research Support: Bridge to Life, Gilead, Novartis, Sanofi

Raymond Chung, MD, FAASLD (Governing Board)
Grant/Research Support: AbbVie, Boehringer Ingelheim, Gilead

Mark Czaja, MD, FAASLD (Governing Board)
Consulting: Verlyx Pharma Inc., Genzyme
Advisory Committee or Review Panel: Verlyx Pharma Inc.
Grant/Research Support: Verlyx Pharma Inc.

Robert Fontana, MD, FAASLD (Clinical Research Committee)
Consulting: CLDF
Grant/Research Support: Bristol-Myers Squibb, Gilead, Jansen

Kimberly Forde, MD, MHS (Clinical Research Committee)
Nothing to Disclose

Michael W. Fried, MD, FAASLD (Governing Board)
Advisory Committee or Review Panel: AbbVie, Bristol-Myers Squibb, Gilead, Merck
Stock/Options: TARGET PharmaSolutions
6